United KingdomA new study published in The Lancet Diabetes and Endocrinology warns of a potential link between SGLT2 inhibitors like dapagliflozin, empagliflozin, canagliflozin, and ertugliflozin and ketoacidosis, a life-threatening condition where harmful ketones accumulate in the blood. Researchers from Karolinska Institute analyzed data from 280,000 type 2 diabetes patients and found that individuals with low body weight, a history of ketoacidosis, high blood sugar, or malnutrition are at increased risk. The study notes that while these medications offer significant benefits for managing diabetes, including weight loss and protection against heart failure and kidney disease, the risks highlight the need for careful monitoring. Previous research from Imperial College London reported an 81% increase in ketoacidosis cases between 2015 and 2023. Patients experiencing symptoms such as excessive thirst, frequent urination, stomach pain, confusion, or fruity-smelling breath should seek immediate medical attention.
Bias read (Center): The article presents a scientific study without overt ideological framing. It discusses medical findings and risks associated with certain medications without promoting any political agenda. The tone remains objective, focusing on health implications rather than partisan perspectives.
